SCHEDULE 13G/A: Paradigm BioCapital Discloses 4.9% Stake in Agios Pharma

Paradigm BioCapital Advisors LP and related entities have disclosed a 4.9% beneficial ownership stake in Agios Pharmaceuticals, Inc., totaling 2,873,555 shares.

Summary

• Paradigm BioCapital Advisors LP, along with Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D., reported beneficial ownership of 2,873,555 shares of Agios Pharmaceuticals, Inc. common stock.
• This aggregate amount represents 4.9% of the outstanding common stock of Agios Pharmaceuticals, Inc.
• The ownership is based on 58,279,876 shares of Common Stock outstanding as of September 30, 2025, as reported in the Issuer's Form 10-Q filed on October 30, 2025.
• The reported shares include 2,673,555 common shares (2,359,870 held by Paradigm BioCapital International Fund Ltd. and 313,685 by separately managed accounts).
• Additionally, 200,000 common shares underlying call options exercisable within 60 days are included (176,300 attributable to the Fund and 23,700 to the Account).
• Paradigm BioCapital International Fund Ltd. separately reported beneficial ownership of 2,536,170 shares, representing 4.4% of the class.
• The securities were not acquired and are not held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, a significant stake by an investment firm can be interpreted as a vote of confidence in the issuer's value or future prospects, especially when declared as a passive investment.

Positives

• A significant investment firm, Paradigm BioCapital, has taken a notable stake in Agios Pharmaceuticals, potentially signaling confidence in the company's future prospects.
• The investment is passive, indicating no immediate intent to disrupt management or strategy, which can be viewed positively by current management and long-term investors.

Negatives

• The filing itself does not contain any negative financial or operational information about Agios Pharmaceuticals, Inc.

Risks

• The filing does not explicitly mention risks related to Agios Pharmaceuticals, Inc. beyond the inherent risks of investing in common stock.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by an investment firm like Paradigm BioCapital in a biotechnology company such as Agios Pharmaceuticals is a common occurrence in the industry, reflecting investment strategies focused on growth potential in the pharmaceutical sector. Such filings provide transparency regarding institutional holdings.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a nearly 5% stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: The filing indicates a passive investment, suggesting no immediate intent to influence control, which may allow management to continue executing its strategy without external pressure from this specific investor.

Key Dates

Keywords

Agios Pharmaceuticals, Paradigm BioCapital, Beneficial Ownership, Common Stock, SEC Filing, Investment, Biotechnology, Pharmaceuticals, AGIO